Survival analysis demonstrated no significant difference in the OS rate between the ICI‐treated (receiving anti‐PD1/PD‐L1 immunotherapy) and TCGA (without ICI treatment) glioblastoma patients (p = 0.55) (Figure 1A). Here, CD274 is linked to glioblastoma.